[Intranasal premedication of young children using midazolam (Dormicum). Clinical experience].
The effect of 0.2 mg/kg body weight intranasal midazolam as a premedicant was investigated in 38 children (age 2-13 years, body weight 10-28 kg) prior to ENT surgery. Intranasal midazolam showed a rapid onset of action with 79% and 95% of the children being sufficiently premedicated at 5 minutes (p less than 0.05) and 10 minutes (p less than 0.01) after application, respectively, as opposed to 45% prior to this. This finding is in keeping with pharmacokinetics showing a tmax of intranasal midazolam of 11 minutes and a bioavailability of 51% in children (10). With the advent of a higher concentrated solution of midazolam intranasal application is also conceivable as a premedication in adults.